Mobile

A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydrochl...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003963-30

A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydrochlorothiazide 25 mg in Comparison with Candesartan Cilexetil 32 mg, Hydrochlorothiazide 25 mg and Placebo in Hypertensive Adults

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1.To compare sitting DBP lowering effect of candesartan cilexetil (candesartan)/hydrochlorothiazide (HCT) 32/25 mg with that of candesartan 32 mg. 2. To compare sitting Systolic Blood Pressure (SBP) lowering effect of candesartan /HCT 32/25 mg with that of candesartan 32 mg. 3. To compare sitting DBP lowering effect of candesartan/HCT 32/25 mg with that of HCT 25 mg. 4. To compare sitting SBP lowering effect of candesartan/HCT 32/25 mg with that of HCT 25 mg.

Critère d'inclusion

  • Hypertension

Liens